Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy
Helio S SaderRonald N Jones

Abstract

Two investigational anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) beta-lactams, ceftaroline (a cephalosporin) and ME1036 (a carbapenem), were subjected to susceptibility testing by reference broth microdilution methods using 152 strains of community-acquired MRSA from the United States (47 medical centers). Ceftaroline and ME1036 were 64- and >128-fold more potent than ceftriaxone, respectively. All isolates had the Panton-Valentine leukocidin genes and staphylococcal cassette chromosome mec type IV, while 67.8% of isolates displayed pulsed-field gel electrophoresis clonal type USA300-0114.

References

Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·Mizuyo KurazonoMinoru Yonezawa
Aug 4, 2004·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yuji IizawaKenji Okonogi
Apr 28, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kumiko MaedaMatsuhisa Inoue
Mar 30, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R H DeurenbergE E Stobberingh
Jun 6, 2007·The Journal of Antimicrobial Chemotherapy·Shazad MushtaqDavid M Livermore
Jun 20, 2007·Antimicrobial Agents and Chemotherapy·Catarina MilheiriçoHermínia de Lencastre

❮ Previous
Next ❯

Citations

Aug 29, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert K FlammRonald N Jones
Jan 26, 2010·The Journal of Antimicrobial Chemotherapy·Hélène MoisanFrançois Malouin
Dec 9, 2010·The Journal of Antimicrobial Chemotherapy·Robert C Moellering
Apr 22, 2011·The Journal of Antimicrobial Chemotherapy·George L Drusano
Nov 3, 2010·Antimicrobial Agents and Chemotherapy·David R SnydmanLaura A McDermott
Feb 24, 2011·Antimicrobial Agents and Chemotherapy·Catherine ClarkKlaudia Kosowska-Shick
May 18, 2011·Antimicrobial Agents and Chemotherapy·Delphine Croisier-BertinPascal Chavanet
Jan 27, 2010·Antimicrobial Agents and Chemotherapy·D M CitronE J C Goldstein
Mar 24, 2010·Antimicrobial Agents and Chemotherapy·Michael R JacobsRonald N Jones
Jan 30, 2013·Antimicrobial Agents and Chemotherapy·Todd A RiccobeneLily Llorens
Jan 1, 2009·Infection and Drug Resistance·William J PeppardJamie Winner
May 2, 2012·Therapeutics and Clinical Risk Management·Julian J Goodman, Stanley I Martin
Feb 12, 2009·Future Microbiology·Zeina A Kanafani, G Ralph Corey
Dec 18, 2010·Future Microbiology·Zeina A Kanafani
Sep 26, 2013·Antimicrobial Agents and Chemotherapy·Xavier HenryBernard Joris
Aug 20, 2014·Infectious Diseases and Therapy·Debbie-Ann T ShirleyJ Kristie Johnson
Nov 22, 2012·Expert Review of Anti-infective Therapy·Mark W GarrisonMary M Wen
Dec 5, 2008·Expert Review of Anti-infective Therapy·David J HerrmannBryan J Buechel
Oct 14, 2008·Expert Review of Anti-infective Therapy·Natasha V D V Ratnaraja, Peter M Hawkey
May 19, 2012·Expert Opinion on Pharmacotherapy·Anthony M CasapaoMichael J Rybak
Jul 16, 2013·Expert Opinion on Emerging Drugs·Adamantia Liapikou, Antoni Torres
Jun 4, 2008·Expert Opinion on Pharmacotherapy·Edina Avdic, Sara E Cosgrove
Oct 28, 2014·Expert Opinion on Drug Metabolism & Toxicology·Andrew MerkerRobert C Glowacki
Apr 21, 2010·Expert Opinion on Pharmacotherapy·Esteban C NanniniG Ralph Corey
Sep 6, 2011·European Journal of Medicinal Chemistry·Bhuwan B Mishra, Vinod K Tiwari
Aug 21, 2010·International Journal of Antimicrobial Agents·Tobias Welte, Mathias W Pletz
Mar 26, 2010·Pharmacotherapy·Molly E Steed, Michael J Rybak
Mar 23, 2011·International Journal of Antimicrobial Agents·Darpan KaushikAnkit Jain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.